Name: Latest research reports of Eris Lifesciences Ltd. authored by BOB Capital Markets Ltd. and published by - Trendlyne research reports.
Item: Eris Lifesciences Ltd.
Rating: 5
Author: BOB Capital Markets Ltd.

Eris Lifesciences Ltd.

NSE: ERIS | BSE: 540596 | ISIN: INE406M01024 | Industry: Pharmaceuticals
| Turnaround Potential

1618.0000 -9.90 (-0.61%)

NSE Jun 26, 2025 15:48 PM

63.91% Gain from 52W Low

Volume: 75,791

Eris Lifesciences Ltd.

22 May 2024

1618.00

-0.61%

Eris Lifesciences (BUY): Strong revenue growth; integration ongoing

Buy: Eris Lifesciences Ltd.

Target

BOB Capital Markets Ltd.

ERIS posted strong revenue performance in Q4 with a beat of 8%, but EBITDA came below BBG consensus due to higher opex and one-offs

Eris Lifesciences Ltd. has gained 59.45% in the last 1 Year